|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1399 NEW YORK AVENUE NW |
Address2 | SUITE 300 |
City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Evan L. Morris, Vice President, Government Affairs |
Date | 07/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Following issues related to the budget and appropriations process; Issues related to government purchases of pandemic drugs: Tamiflu; Seek Federal appropriations in the FY11 Labor, Health and Human Services and Education bill regarding pandemic influenza;HIV/AIDS programs and HCV screening, care and treatment; Implementation of H.R. 2346, S. 10554;
FY09 Supplemental Appropriations related to preparedness for pandemic influenza;
FY11 State Foreign Operations appropriations related to USAID and funding for Pandemic Influenza
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Katherine |
Martin |
|
|
|
David |
Burt |
|
|
|
Anna |
Sagely |
|
|
|
Darin |
Gardner |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Patent Settlement Issues; Intellectual Property and Process Patent Issues; H.R. 1908; S. 515 & HR. 1260 - Patent Reform Act of 2009; Monitor legislation regarding brand name and generic pharmaceutical agreement, patent fees, and post-grant review reforms.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Katherine |
Martin |
|
|
|
David |
Burt |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Monitor and report on corporate tax issues; Monitoring proposals on U.S. tax treatment of foreign corporations; S. 506, Stop Tax Haven Abuse Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Pandemic Preparedeness: Tamiflu; Advocate on legislative changes in the health care reform bill regarding biosimilars; Monitor changes to outpatient 340B presecription drug discount program, including related provisions included in HR 4213 - American Jobs and Closing Tax Loopholes Act, and ddraft Senate amendments to the legislation; Labor, Health and Human Services Appropriations bill; H.R. 1548 - Pathway for Biosimilars Act; Health care and biotechnology legislation, including H.R. 3490;
Implementation of P.L. 111-148, "Patient Protection and Affordable Care Act" and P.L. 111-152, "Reconciliation Act of 2010", including comparative effectiveness provisions;
S. 726/H.R. 1427 - Promoting Innovation and Access to Life-Saving Medicine Act;
H.R. 1548 - Pathway for Biosimilars Act;
Physician payment disclosure including S. 301; Physician Payments Sunshine Act of 2009; H.R. 3962, Affordable Health Care for Americans Act; H.R. 3590;
Patient Protection and Affordable Care Act
H.R. 4872, the Reconciliation Act of 2010;
Follow on biologics includuing H.R. 154, the Pathway to Biosimilars Act;
S. 726/H.R. 1427, Promoting Innovation and Access to Life Savings Medicines Act;
H.R. 3962, Affordable health care for America Act;
Comparative effectiveness legislation including S. 1213;
Patient-Centered Outcomes Research Act of 2009;
H.R. 3200, America's Health Future Act;
H.R. 1548 - Pathway for Dissimilar Act;
Legislative changes in the heatlh care reform bill regarding dissimilars;
S. 1679 Affordeable Health Choice Act;
S.1796, America's Health future Act of 2009;
Pharmacuetical import safety legislation.
H.R. 1105 Omnibus Appropriations Act of 2010;
Supplemental Appropriations Act of 2010, Food Safety
Issues concerning clinlical trials;
H.R. 3974, Viral Hepatitis and Liver Cancer Control and Prevention Act of 2009
H.R. 3590 Patient Protetion and Affordable Care Act - FTC issue
Ryan White CARE Act reauthorization
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Labor HHS Appropriations - S. 3230 and H.R. 3042
Homeland Security Appropriations S.3181 and H.R. 6947
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS), Executive Office of the President (EOP), Office of Personnel Management (OPM), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Monitoring proposals on U.S. tax treatment of foreign corporations
S. 506, Stop Tax Haven Abuse Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
` |
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Monitor food safety and supply chain issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Monitor issues related to export rules and regulations
International patent issues
WTO matters and other international trade issues impacting biotech and pharmaceuticals
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
David |
Burt |
|
|
|
Katherine |
Martin |
|
|
|
Anna |
Sagely |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Monitor implementation of Medicare pharmaceutical coverage and reimbusement provisions of P.L. 111-148 - Patient protection and Affordable CAre Act and P.L. 111-152 - Health Care and Education Reconciliation Act; Implementation of H.R. 1; Medicare Prescription Drug and Modernization Act of 2003; Medicare and Medicaid Coverage and Reimbursement; issues relating to Prescription Drug User Fee Act, stimulus provisions and economic recovery;
Issues related to comparative effectiveness and follow-on biologics;
H.R. 3200 and America's health Future Act of 2009;
H.R. 4213, the American jobs, Closing Tax Loopholes and Preventing Outsourcing Act of 2010 - eligibility changes for the 340B program, treatment of certain drugs for computation of Average Manufacturer's Price under the Medicaid program;
Participatd in discussions with Senate Aging Comm staff on Medicare coverage payment issues related to cancer biotherapeutics;
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP), Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
|
|
Darin |
Gardner |
|
|
|
Anna |
Sagely |
|
|
|
Katherine |
Martin |
|
|
|
David |
Burt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
5 |
|
||||||
2 |
|
6 |
|
||||||
3 |
|
7 |
|
||||||
4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 3 | 5 |
2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 5 | 9 |
2 | 6 | 10 |
3 | 7 | 11 |
4 | 8 | 12 |